Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Lynn M. Pezzanite
 + 2121 word(s) 2121 2021-11-15 10:23:18 |
2 format correct
Catherine Yang
 Meta information modification 2121 2022-01-13 01:57:05 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Pezzanite, L.M. Innate Immunity and Osteoarthritis. Encyclopedia. Available online: https://encyclopedia.pub/entry/18154 (accessed on 16 November 2024).
Pezzanite LM. Innate Immunity and Osteoarthritis. Encyclopedia. Available at: https://encyclopedia.pub/entry/18154. Accessed November 16, 2024.
Pezzanite, Lynn M.. "Innate Immunity and Osteoarthritis" Encyclopedia, https://encyclopedia.pub/entry/18154 (accessed November 16, 2024).
Pezzanite, L.M. (2022, January 12). Innate Immunity and Osteoarthritis. In Encyclopedia. https://encyclopedia.pub/entry/18154
Pezzanite, Lynn M.. "Innate Immunity and Osteoarthritis." Encyclopedia. Web. 12 January, 2022.
Innate Immunity and Osteoarthritis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ani11113247

The innate immune system is classically triggered by host responses to pathogen-associated molecular patterns (PAMPs) induced by interactions with invariable pattern-recognition receptors (PRRs) on synovial joint immune cells such as neutrophils, macrophages, monocytes, and dendritic cells (DC). PRRs are comprised of a family of cell surface, endosomal and cytosolic receptors, including Toll-like receptors and NOD-like receptors. Activation of PRRs within tissues such as the joint leads initially to rapid-onset inflammatory responses, followed later by initiation of adaptive immune responses and finally by healing responses in the case of tissue injuries.

osteoarthritis innate immunity

1. Pattern Recognition Receptors and Immune Cells in Joints

Although understanding of OA pathogenesis is still evolving, innate immune cells, particularly myeloid cells, play a role in regulating and perpetuating low-grade inflammation that characterizes Osteoarthritis (OA)  (Figure 1). Histologically, synovial inflammation in OA is characterized by transient and/or cyclical hyperplasia of the synovial lining cells accompanied by inflammatory cell infiltration. This population consists predominantly of macrophages and smaller numbers of T and B cells, mast cells, and natural killer (NK) cells [1][2][3][4].
Animals 11 03247 g001 550
Figure 1. Role of synovial resident macrophages and inflammatory macrophages in joint health and osteoarthritis. This figure illustrates the complex interaction between endogenous self-renewing synovial cell macrophages, which exist as M2 cells in the healthy joint, and the inflammatory macrophage M1 population recruited from inflammatory monocytes in blood in response to chemokines produced during joint inflammation occurring during the progression of OA. While M1 macrophages may assume an M2 phenotype as inflammation subsides, endogenous M2 macrophages typically do not generate M1 macrophages. The factors secreted by synovial M1 and M2 macrophage populations in health and disease are complex and largely distinct. Abbreviations: tumor necrosis factor (TNF); interleukin 1Β (IL-1Β); interleukin 6 (IL-6), Myeloid protein SN100A8/A9; C-X-C Motif Chemokine Ligand 8 or Interleukin-8 (CXCL8); (CCL2); matrix metalloproteinase (MMP); interleukin 10 (IL-10); synovial fluid (SF); vascular endothelial growth factor (VEGF); transforming growth factor B (TGF-B).
The innate immune system is classically triggered by host responses to pathogen-associated molecular patterns (PAMPs) induced by interactions with invariable pattern-recognition receptors (PRRs) on synovial joint immune cells such as neutrophils, macrophages, monocytes, and dendritic cells (DC). PRRs are comprised of a family of cell surface, endosomal and cytosolic receptors, including Toll-like receptors and NOD-like receptors [5]. Activation of PRRs within tissues such as the joint leads initially to rapid-onset inflammatory responses, followed later by initiation of adaptive immune responses and finally by healing responses in the case of tissue injuries.
In addition to invading pathogens, PRRs also recognize various endogenous “danger signals,” known as damage associated molecular patterns (DAMPs), triggered from cell or tissue damage. Non-infectious DAMPs (e.g., cartilage degradation products) can activate macrophages and DCs, including inflammasome activation, initiation of cellular pyroptosis, and other unfolded protein responses that induce inflammatory, metabolic, and adaptive immune pathologies [6][7]. The list of known DAMPs is rapidly growing and beyond the scope of this review. Studies have shown that cartilage injury results in the release of DAMPs within the joint, including breakdown products from fibronectin and hyaluronan [8][9][10].

2. Macrophages and OA

Macrophages are central players in host defense and are distributed in almost all tissues, having unique functions in each organ depending on the specific microenvironment that influences their functional properties. In addition to their more familiar functions as proinflammatory, scavenger, antimicrobial, and antitumor defense effector/mediators, macrophages also function as immune modulators, promoting anti-inflammatory and tissue repair processes [11][12][13][14][15]. Given their central role in OA, a clinical approach targeting activated macrophages at an earlier stage of OA may serve to inhibit or slow the progression of disease [16][17].
Tissue macrophages such as alveolar macrophages and Kupffer cells are derived from the yolk sac during early embryogenesis and serve as a self-renewing population of tissue macrophages throughout life. It is likely that synovial macrophages are also a unique tissue specific population of self-renewing cells, which have an important role in maintaining articular homeostasis. Inflammatory monocytes by contrast reach the joint following release from the bone marrow and differentiate into short-lived inflammatory macrophages in synovial tissues (Figure 1). Macrophages in tissues are classified as proinflammatory (M1) or anti-inflammatory (M2) cells [18]. In rheumatoid arthritis, the majority of M1 macrophages are bone marrow-derived and are recruited to and differentiate within the joint. In vivo heterogeneity varies between M1 and M2 populations have been identified using next-generation sequencing technologies and transcriptomic analysis [19]. The rationale for having seemingly opposing systems is to achieve immune homeostasis via a proper balance of M1 and M2 responses, thereby maintaining a tightly controlled immune environment capable of optimal protection while preventing host tissue destruction. This is a very important consideration as macrophages are the more numerous immune cells in the synovium and further understanding is paramount before they can be exploited for therapeutic purposes [19][11][20].
M1 macrophages typically have multiple functions and are responsible for the release of molecules that can drive inflammation. M1 macrophages are differentially stimulated by NK cells and NK T cell secretion of IFNγ, by various TLR agonists such as bacterial lipopolysaccharide (LPS), or growth factors such as granulocyte-macrophage-colony-stimulating factor (GM-CSF). M2 macrophages, on the other hand, are functionally considered to be more anti-inflammatory and viewed as mediating an opposing immune regulatory response that counters proinflammatory M1 responses and abrogates host tissue destruction. M2 macrophages are stimulated by IL-4 and IL-13 secreted primarily by Th2 T cells, mast cells and, more recently discovered, by basophils—to produce mostly anti-inflammatory cytokines such as IL-10, IL-1ra, TGFβ, and arginase-1 (Arg-1) [13][21]. Under a homeostatic state, most macrophages display the M2 phenotype to maintain tissue surveillance and protect against metabolically derived oxidative conditions and inflammation [22]. Specifically, CD206+ M2 macrophages produce IL-4, IL-10, and MMP-12, which reduces neutrophil influx to the joint and can counter the inflammatory response and catabolic effects seen in OA [19][23][11][12][14][15][24][25][26][27][28][29][30].
When activated, CD80/86+ M1 macrophages secrete high levels of proinflammatory cytokines such as IL-1β, IL-6, IL-8, IL-12, TNFα, and alarmins; they also induce Th1 adaptive immune responses [11]. These synovial macrophages, in turn, activate the production of harmful molecules such as matrix metalloproteinases (MMP-1, MMP-3, MMP-8, MMP-9, MMP-13) from other innate immune system cells and synovial fibroblasts, causing generation of DAMPs from extra cellular matrix (ECM) degeneration [11]. Additionally, pro-inflammatory cytokines stimulate synthesis of PGE2 by cyclo-oxygenase-2, microsomal PGE synthase-1, and soluble phospholipase A2 [31][11] This is associated with production of nitric oxide (NO) by nitric oxide synthetase, reactive oxygen species (ROS), 5-lipoxygenase and leukotriene B4 [11]. This pro-inflammatory environment also favors the activation of neuropeptides, such as substance P, that increase inflammation and result in joint pain [31][11].
Over-production of M1-derived cytokines, growth factors, various proteases, and oxidizers in inflamed synovium can heavily contribute to the initiation and progression of OA via DAMP-driven cellular pyroptosis [11][32][33][34]. DAMP activation of synovial macrophages in OA produces ROS that may incite the Nod-like receptor protein 3 (NLRP3) component of the caspase-1-activating inflammasome, mediating secretion of pro-inflammatory cytokines IL-1β, IL-18, and TNFα [11]. DAMPs identified in this process include degradation products from hyaluronidase, hydroxyapatite (HA) and basic calcium phosphate (BCP) crystals from cartilaginous calcification [11]. Although inflammasomes in veterinary species have not been well characterized, recent work has demonstrated that equine peripheral blood mononuclear cells (PBMCs) normally secrete IL-1β in response to well-known inflammasome activators of NLRP3 [32][33][34]. The key transcription factor countering the resulting oxidative stress is nuclear factor E2-related factor 2 (Nrf2), which protects against oxidative stress and tissue damage. Accordingly, future research into the signaling mechanisms transducing the Nrf2-mediated transcriptional program may serve to develop novel therapies for OA [35][36][37][38][39].
It should be noted that, in vivo, macrophages do not adhere to strict dichotomous phenotypes, but rather express plasticity across the spectrum between M1 and M2, capable of signaling for either inflammation or healing depending on tissue milieu [11]. For example, availability of various DAMPs within the joint microenvironment, their anatomical origin, and the tissue in which they are located, may influence macrophage phenotype, making it difficult to ensure that all CD86+ macrophages exclusively perform M1 functions and that all CD206+ macrophages exclusively assist in healing and resolution of inflammation. Thus, caution should be taken when describing the overall pro- vs. anti-inflammatory status within a locale [19][12]. Furthermore, studies involving murine models of macrophage depletion have reported mixed results, suggesting that this therapy might vary greatly between tissues and might not always be beneficial as all populations of myeloid cells are affected, including DCs and neutrophils [19].

3. Value of Equine Models for OA Research

Many factors can influence the outcome of data acquired from the various animal models of OA, such as overall intrinsic species and strain variation, age, sex, housing, time of intervention, stress levels, and activity. These are important considerations that must be taken into account when assessing the outcome of any project involving knowledge gathered regarding the predisposition, cause, and ultimate therapeutic success of a given research approach [40]. In vitro models are affordable and make it easier to control many variables at the same time, but the bi-dimensional model does not fully represent what truly happens in the joint. Three-dimensional models, including explants, scaffold-based and scaffold-free systems, provide a more similar environment to the joint and its interaction with the cells while allowing more variable control. In vivo models, especially large animals, remain a more viable option due to anatomic similarities and naturally occurring OA [41].
Although data from murine models is very informative and valuable in biomedical research, the variance in the programmed genomic responses to acute inflammatory responses and their significant anatomical differences might not make them the best translational option for human or equine patients [42]. From an anatomical perspective, the horse model of OA most closely resembles humans with regard to articular cartilage thickness [43]. In addition, horses suffer from OA frequently and spontaneously, providing veterinarians with significant experience in treating the condition. The equine carpal chip model of OA represents a predictable model with which to test novel approaches such as immunomodulating therapies like mesenchymal stromal cells (MSCs) [44]. Accordingly, horses are one of the best animals to use as a model for human OA, due to similarities in many of the joints’ movement and comparable cartilage and subchondral bone thicknesses [45][46].

4. Equine Innate Immune System and OA

Of the structures present in the joint, the most relevant regarding its capacity to mount an inflammatory response is the synovium. The cells that are recruited and react to post-traumatic osteoarthritis are components of the innate immune system and are mainly resident macrophages. Destruction of cartilage matrix by MMPs will result in the immediate production of IL-1β and TNFα, and these powerful pro-inflammatory cytokines can perpetuate the inflammatory cascade and pain in the joint [25][47]. Although there is a strong correlation between obesity and chronic inflammation in humans and mice [48], such a comparison has not been made for horses and it is likely that post-traumatic injury is the more common cause of OA in horses.
Synovium and innate immunity—The synovium is the major site of articular inflammation in OA and is often marked by hyperplasia of the synovial lining cells coupled with infiltration of inflammatory cells consisting mostly of macrophages and smaller numbers of other cells [1][2][3][4]. The macrophage population in the synovium is classified into two groups: 25% of the cells are type A synovial cells (macrophages) and 75% of the cells are type B synoviocytes (fibroblast-like) [49]. Also, macrophages can be found in synovial fluid and can account for 70% of the total cells in a non-inflamed joint, with these numbers increasing up to 90% in an inflammation model for repeated arthrocentesis [50]. Thus, immune cells constitute a significant percentage of all the cells in joint tissues and synovial fluid.
Cartilage and innate immunity—Mature equine cartilage predominantly contains chondrocytes, including only a very small population of progenitor cells. Cartilage is a firm yet smooth, lubricated, and almost frictionless surface that enables normal joint function and depends on the synovium for lubrication. It is important to consider that cartilage is an aneural and avascular tissue, depending directly for their metabolic support on factors present in synovial fluid. Cartilage also reacts to inflammatory reactions triggered in the synovium. It is also important to note that cartilage degradation products in synovial fluid, as well as micro-fissures in articular tissue, are often present before any degeneration can be detected using current imaging technology. It has been speculated that early cartilage degradation events may drive the development of inflammation within OA synovium, which happens through the activation of resident macrophages through DAMPS favoring the release of TNFα and IL-1β that will, in turn, increase the MMPs production by the chondrocytes [23][50].
Subchondral bone and innate immunity—Subchondral bone differs significantly from cartilage, as it is heavily vascularized, allowing for major tissue turnover and the ability to remodel to adapt to mechanical loads. Inflammation of the subchondral bone can lead to the production of angiogenic factors and local MMP production, which is thought to stimulate cartilage degeneration and the formation of osteophytes [23][51][52].

References

  1. Sellam, J.; Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. 2010, 11, 625–635.
  2. Bondeson, J.; Wainwright, S.D.; Lauder, S.; Amos, N.; Hughes, C.E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res. Ther. 2006, 8, R187.
  3. Dean, G.; Hoyland, J.A.; Denton, J.; Donn, R.P.; Freemont, A.J. Mast cells in the synovium and synovial fluid in osteoarthritis. Rheumatol. 1993, 32, 671–675.
  4. Steel, C.M. Equine Synovial Fluid Analysis. Vet. Clin. N. Am. Equine Pract. 2008, 24, 437–454.
  5. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010, 11, 373–384.
  6. Cao, S.S.; Kaufman, R.J. Unfolded protein response. Curr. Biol. 2012, 22, R622–R626.
  7. Bergsbaken, T.; Fink, S.L.; Cookson, B.T. Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7, 99–109.
  8. Okamura, Y.; Watari, M.; Jerud, E.S.; Young, D.W.; Ishizaka, S.T.; Rose, J.; Chow, J.C.; Jerome, S.F., III. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001, 276, 10229–10233.
  9. Termeer, C.; Benedix, F.; Sleeman, J.; Fieber, C.; Voith, U.; Ahrens, T.; Miyake, K.; Freudenberg, M.; Galanos, C.; Simon, J.C. Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4. J. Exp. Med. 2002, 195, 99–111.
  10. Sohn, D.H.; Sokolove, J.; Sharpe, O.; Erhart, J.C.; Chandra, P.E.; Lahey, L.J.; Lindstrom, T.M.; Hwang, I.; Boyer, K.A.; Andriacchi, T.P.; et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res. Ther. 2012, 14, R7.
  11. Chen, Y.; Jiang, W.; Yong, H.; He, M.; Yang, Y.; Deng, Z.; Li, Y. Macrophages in osteoarthritis: Pathophysiology and therapeutics. Am. J. Trans. Res. 2020, 12, 261–268.
  12. Menarim, B.C.; Gillis, K.H.; Oliver, A.; Mason, C.; Ngo, Y.; Werre, S.R.; Barrett, S.H.; Luo, X.; Byron, C.R.; Dahlgren, L.A. Autologous bone marrow mononuclear cells modulate joint homeostasis in an equine in vivo model of synovitis. FASEB J. 2019, 33, 14337–14353.
  13. Hawkins, D.L.; MacKay, R.J.; MacKay, S.L.D.; Moldawer, L.L. Human interleukin 10 suppresses production of inflammatory mediators by LPS-stimulated equine peritoneal macrophages. Vet. Immunol. Immunopathol. 1998, 66, 1–10.
  14. Karagianni, A.E.; Kapetanovic, R.; McGorum, B.C.; Hume, D.A.; Pirie, S.R. The equine alveolar macrophage: Functional and phenotypic comparisons with peritoneal macrophages. Vet. Immunol. Immunopathol. 2013, 155, 219–228.
  15. Wilson, M.E.; McCandless, E.E.; Olszewski, M.A.; Robinson, N.E. Alveolar macrophage phenotypes in severe equine asthma. Vet. J. 2020, 256, 105436.
  16. Murray, P.J.; Wynn, T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11, 723–737.
  17. Yang, D.H.; Yang, M.Y. The Role of Macrophage in the Pathogenesis of Osteoporosis. Int. J. Mol. Sci. 2019, 20, 2093.
  18. Murray, P.J. Macrophage Polarization. Annu. Rev. Physiol. 2017, 79, 541–566.
  19. Wu, C.L.; Harasymowicz, N.S.; Klimak, M.A.; Collins, K.H.; Guilak, F. The role of macrophages in osteoarthritis and cartilage repair. Osteoarthr. Cartilage 2020, 28, 544–554.
  20. Sommerfeld, S.D.; Cherry, C.; Schwab, R.M.; Chung, L.; Maestas, D.R.; Laffont, P.; Stein, J.; Tam, A.; Housseau, F.; Taube, J. Single cell RNA-seq in regenerative and fibrotic biomaterial environments defines new macrophage subsets. Sci. Immunol. 2019, 642389.
  21. Yoshimoto, T. The Hunt for the Source of Primary Interleukin-4: How We Discovered That Natural Killer T Cells and Basophils Determine T Helper Type 2 Cell Differentiation In Vivo. Front. Immunol. 2018, 9, 716.
  22. Dey, A.; Allen, J.; Hankey-Giblin, P.A. Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes Versus Tissue Macrophages. Front. Immunol. 2015, 5, 683.
  23. McIlwraith, C.W. Traumatic Arthritis and Post-Traumatic Osteoarthritis. In Joint Disease in the Horse, 2nd ed.; McIlwraith, C.W., Frisbie, D., Kawcak, C., van Weeren, R., Eds.; Elsevier: St. Louis, MO, USA; Amsterdam, The Netherlands, 2016; pp. 33–48.
  24. Murray, P.J.; Allen, J.E.; Biswas, S.K.; Fisher, E.A.; Gilroy, D.W.; Goerdt, S.; Gordon, S.; Hamilton, J.A.; Ivashkiv, L.B.; Lawrence, T.; et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 2014, 411, 14–20.
  25. Duan, L.; Mukherjee, E. Janeway’s Immunobiology, Ninth Edition. Yale J. Biol. Med. 2016, 89, 424–425.
  26. van den Bosch, M.H.J.; van Lent, P.L.E.M.; van der Kraan, P.M. Identifying effector molecules, cells, and cytokines of innate immunity in OA. Osteoarthr. Cartilage 2020, 28, 532–543.
  27. Griffin, T.M.; Lories, R.J. Cracking the code on the innate immune program in OA. Osteoarthr. Cartilage 2020, 28, 529–531.
  28. Menarim, B.C.; Gillis, K.H.; Oliver, A.; Mason, C.; Were, S.R.; Luo, X.; Byron, C.R.; Kalbfleisch, T.S.; MacLeod, J.N.; Dahlgren, L.A. Inflamed synovial fluid induces a homeostatic response in bone marrow mononuclear cells in vitro: Implications for joint therapy. FASEB J. 2020, 34, 4430–4444.
  29. Bullone, M.; Lavoie, J.P. The Contribution of Oxidative Stress and Inflamm-Aging in Human and Equine Asthma. Int. J. Mol. Sci. 2017, 18, 2612.
  30. Karagianni, A.E.; Kapetanovic, R.; Summer, K.M.; Mcgorum, B.C.; Hume, D.A.; Pirie, R.S. Comparative transcriptome analysis of equine alveolar macrophages. Equine Vet. J. 2017, 493, 375–382.
  31. van Weeren, P.R.; de Grauw, J.C. Pain in Osteoarthritis. Vet. Clin. N. Am. Equine Pract. 2010, 26, 619–642.
  32. Ross, T.N.; Kisiday, J.D.; Hess, T.; McIlwraith, C.W. Evaluation of the inflammatory response in experimentally induced synovitis in the horse: A comparison of recombinant equine interleukin 1 beta and lipopolysaccharide. Osteoarthr. Cartilage 2012, 20, 1583–1590.
  33. Hammond, R.A.; Hannon, R.; Frean, S.P.; Armstrong, S.J.; Flower, R.J.; Bryant, C.E. Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Am. J. Vet. Res. 1999, 60, 426–431.
  34. Moore, B.D.; Balasuriya, U.B.R.; Watson, J.L.; Bosio, C.M.; MacKay, R.J.; MacLachlan, N.J. Virulent and avirulent strains of equine arteritis virus induce different quantities of TNF-α and other proinflammatory cytokines in alveolar and blood-derived equine macrophages. Virology 2003, 314, 662–670.
  35. So, A.; Busso, N. The concept of the inflammasome and its rheumatologic implications. Joint Bone Spine 2014, 5, 398–402.
  36. Netea, M.G.; Nold-Petry, C.A.; Nold, M.F.; Joosten, L.A.B.; Opitz, B.; van der Meer, J.H.M.; van de Veerdonk, F.L.; Ferwerda, G.; Heinhuis, B.; Devesa, I.; et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009, 113, 2324–2335.
  37. Chen, Z.; Zhong, H.; Wei, J.; Lin, S.; Zong, Z.; Gong, F.; Huang, X.; Sun, J.; Li, P.; Lin, H.; et al. Inhibition of Nrf2/HO-1 signaling leads to increased activation of the NLRP3 inflammasome in osteoarthritis. Arthritis Res. Ther. 2019, 21, 300.
  38. Ahn, H.; Kim, J.; Lee, H.; Lee, E.; Lee, G. Characterization of equine inflammasomes and their regulation. Vet. Res. Commun. 2020, 44, 51–59.
  39. Hennig, P.; Garstkiewicz, M.; Grossi, S.; Di Fillippo, M.; French, L.; Beer, H. The Crosstalk between Nrf2 and Inflammasomes. Int. J. Mol. Sci. 2018, 19, 562.
  40. van der Kraan, P.M. Factors that influence outcome in experimental osteoarthritis. Osteoarthr. Cartilage 2017, 25, 369–375.
  41. Samvelyan, H.J.; Hughes, D.; Stevens, C.; Staines, K. Models of Osteoarthritis: Relevance and New Insights. Calcif. Tissue Int. 2021, 109, 243–256.
  42. Seok, J.; Warren, S.; Cuenca, A.G.; Mindrinos, M.; Baker, H.; Xu, W.; Richards, D.; McDonald-Smith, G.; Gao, H.; Hennessy, L.; et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 2013, 110, 3507–3512.
  43. Frisbie, D.D.; Cross, M.W.; McIlwraith, C.W. A comparative study of articular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee. Vet. Comp. Orthop Traumatol. 2006, 19, 142–146.
  44. McIlwraith, C.W.; Frisbie, D.D.; Kawcak, C.E. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res. 2012, 1, 297–309.
  45. Colbath, A.C.; Frisbie, D.D.; Dow, S.W.; Kisiday, J.D.; McIlwraith, C.W.; Goodrich, L.R. Equine Models for the Investigation of Mesenchymal Stem Cell Therapies in Orthopaedic Disease. Oper. Tech. Sports Med. 2017, 25, 41–49.
  46. Barrachina, L.; Cequier, A.; Romero, A.; Vitoria, A.; Zaragoza, P.; Vazquez, F.J.; Rodellar, C. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: Effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility. Stem Cell Res. Ther. 2020, 11, 52.
  47. Miller, R.J.; Malfait, A.M.; Miller, R.E. The innate immune response as a mediator of osteoarthritis pain. Osteoarthr. Cartilage 2020, 28, 562–571.
  48. Miao, H.; Chen, L.; Hao, L.; Zhang, X.; Chen, Y.; Ruan, Z.; Liang, H. Stearic acid induces pro-inflammatory cytokine production partly through activation of lactate-HIF1α pathway in chondrocytes. Sci. Rep. 2015, 5, 13092.
  49. Di Nicola, V. Degenerative osteoarthritis a reversible chronic disease. Regen Therapy 2020, 15, 149–160.
  50. Rinnovati, R.; Bonelli, F.; Tognetti, R.; Gallo, C. Effect of Repeated Arthrocentesis on Cytology of Synovial Fluid. J. Equine Vet. Sci. 2017, 57, 112–115.
  51. Chevalier, X.; Eymard, F.; Richette, P. Biologic agents in osteoarthritis: Hopes and disappointments. Nat. Rev. Rheumatol. 2013, 9, 400–410.
  52. Yuan, X.L.; Meng, H.Y.; Wang, Y.C.; Peng, J.; Guo, Q.Y.; Wang, A.Y.; Lu, S.B. Bone–cartilage interface crosstalk in osteoarthritis: Potential pathways and future therapeutic strategies. Osteoarthr. Cartilage 2014, 22, 1077–1089.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Orthopedics
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Lynn M. Pezzanite
View Times: 662
Revisions: 2 times (View History)
Update Date: 13 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback